

Anti-14-3-3eta Multiplex for Axial Spondyloarthritis

Bridging critical gaps in axial
spondyloarthritis diagnosis



augurex 

Anti-14-3-3eta Multiplex is the only biomarker for axSpA



What is Axial Spondyloarthritis?

Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac joints, causing pain, stiffness, and joint damage.

Diagnostic Delay

Diagnosis is often **delayed by 7 to 10 years** due to the absence of reliable biomarkers, with many cases misdiagnosed as chronic low back pain. Early detection is critical for preventing long-term damage and improving patient outcomes.¹



What is Anti-14-3-3eta Multiplex?

Anti-14-3-3eta Multiplex ASRs represent a first-in-class diagnostic that detects autoantibodies against the normally intracellular 14-3-3eta protein, a well-established biomarker in autoimmune rheumatologic disorders.

How it works


This novel Luminex[®] assay aids in identifying axSpA early, enabling rheumatologists to administer the right treatment at the right time.

Anti-14-3-3eta Multiplex is highly sensitive and highly specific for early diagnosis of axSpA




Key Features of Anti-14-3-3eta Multiplex

- ① **Early and Accurate Diagnosis:** Anti-14-3-3eta Multiplex is highly sensitive (76%) and highly specific (74%) to enable differentiation between axSpA and healthy controls.²
- ① **Complementary to CRP:** Combined with CRP, the Anti-14-3-3eta Multiplex can identify 90% of axSpA patients, improving diagnostic accuracy.³
- ① **HLA-B27 Independent:** Anti-14-3-3eta Multiplex provides diagnostic value even in patients who are negative for traditional markers like HLA-B27.³



Sensitivity



Specificity



CRP + Anti-14-3-3eta Multiplex identifies 90% of axSpA patients

Key Benefits of Anti-14-3-3eta Multiplex

- ① **Streamlined Diagnostic Process:** Aids in the early and accurate diagnosis of axSpA, reducing the 7-10 year average time to diagnosis.
- ① **Complementary to Imaging:** Offers diagnostic support alongside traditional imaging.
- ① **Clinical Confidence:** Enables evidence-based decisions, leading to more timely and appropriate treatment plans.
- ① **Improved Outcomes:** Anti-14-3-3eta Multiplex aids in earlier detection and intervention of axSpA, potentially preventing long-term spinal damage.

Anti-14-3-3eta Multiplex ASRs Available Nationwide in 2025



Anti-14-3-3eta Multiplex is now available for early access in Knoxville, Tennessee, through our partnership with New Day Diagnostics as a laboratory-developed test (LDT). To order a test, visit <https://newdaydiagnostics.com/spinestat/>.

Expanded national access through leading labs in 2025

To stay informed about updates visit <https://augurex.com/axial-spondyloarthritis/>.

Partner with Augurex

Join us in improving diagnostic options for axSpA. Contact us for more information on how to access Anti-14-3-3eta Multiplex and collaborate to expand testing availability.

Contact



www.augurex.com



+1604-674-8231



info@augurex.com

References

- 1) Lapane KL, Khan S, Shridharmurthy D, Beccia A, Dubé C, Yi E, Kay J, Liu SH. Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. *BMC Fam Pract*. 2020 Sep 29;21(1):204.
- 2) Marotta A, Maksymowych WP, Wichuk S, Sidhu N. P54 Novel Diagnostic 14-3-3 η Auto-Antibody Marker for Axial Spondyloarthritis: A Longitudinal Study. Fourteenth International Congress on Spondyloarthritis. *Clin Exp Rheumatol*. 2024.
- 3) Marotta A, Maksymowych WP, Wichuk S, Sidhu N. POS1094 Autoantibodies to 14-3-3 η in Axial Spondyloarthritis. *Annals of the Rheumatic Diseases*. 2024;83:892-893.